ライフサイエンスコーパス: hematologist

1 written from the perspective of a practicing hematologist.

2 otable therapeutic challenge to the clinical hematologist.

3 rpretation from a radiation oncologist and a hematologist.

4 mbocythemia, presents many challenges to the hematologist.

5 a when treatment was directed by a pediatric hematologist.

6 problem seen by primary care physicians and hematologists.

7 and ubiquitin biology fields as well as from hematologists.

8 ic physicians, rheumatologists, and clinical hematologists.

9 ticipants were oncologists (36.1%; n = 239), hematologists (14.5%; n = 96), radiation oncologists (7.

10 dents included oncologists (38.5%, n = 371), hematologists (16.4%, n = 158), radiation oncologists (9

11 39 physicians); 37% were medical oncologists/hematologists, 50% were radiation oncologists, and 12% w

12 dical directors of blood banks (3 patients), hematologists (6), and the manufacturer of clopidogrel (

13 py before focusing on a frequent question to hematologists about the 2 most commonly used antiplatele

14 Familiar to nephrologists and hematologists alike, classically associated with thrombo

15 to orchestrate processes of interest to the hematologist and more broadly.

16 l of this study was to obtain the opinion of hematologists and medical oncologists about CD20-directe

17 2009, an international workshop attended by hematologists and nuclear medicine experts in Deauville,

18 Hematologists and oncologists are uniquely suited to hel

19 Thus, this national survey of US hematologists and oncologists has identified substantial

20 s review provides a framework for practicing hematologists and oncologists to make rational treatment

21 al advisory committee (CAC) of international hematologists and oncologists was formed to ensure that

22 matopathologists, and more than 100 clinical hematologists and scientists who are internationally rec

23 d, 2 articles by The Nimes Obstetricians and Hematologists-Antiphospholipid Syndrome (NOH-APS) Study

24 Hematologists are often asked to treat patients with ven

25 failure in the pediatric patient places the hematologist at the junction of clinical medicine, cellu

26 nized under the microscope by the practicing hematologist because early institution of all-trans reti

27 Knowledge of these advances is relevant for hematologists because they administer the hematin infusi

28 is highlighted with the aim of familiarizing hematologists, clinical scientists, and hematopathologis

29 Stratton and the prominent hematologist Dr William Dameshek of Tufts School of Medi

30 Benveniste, a hematologist, engineer, skeptic, statistician, neuroscie

31 She was referred to a hematologist for evaluation of persistent isolated throm

32 Patients with celiac disease may present to hematologists for evaluation of various hematologic prob

33 r peculiar characteristics that have puzzled hematologists for more than a century.

34 has long fascinated biologists and attracted hematologists given its importance for patients with hem

35 Moreover, hematologists have also noted that these children common

36 In addition to the severe beta thalassemias, hematologists have begun to recognize the more severe fo

37 986-2006 were confirmed by a panel of expert hematologists/hematopathologists.

38 Drawing on sources produced by hematologists, historian Keith Wailoo has shown that whe

39 some of the variations in phenotype seen by hematologists in patients with identical mutations, to i

40 present to various medical specialties, the hematologist is often consulted to offer the definitive

41 A leading British hematologist, John V. Dacie was known for his pioneering

42 As hematologists make a diagnosis of anemia, which invites

43 d thrombosis paradigms, while the practicing hematologist must appreciate platelet relevance in a wid

44 es evaluation by a multidisciplinary team (a hematologist, neurologist, neuroradiologist, and transfu

45 These developments are reviewed to update hematologists on the latest advances in these diverse di

46 tidisciplinary team including an experienced hematologist/oncologist, a high-risk obstetrics speciali

47 consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists.

48 pathogen is warranted among rheumatologists, hematologists, oncologists, and infectious disease speci

49 zerland, in June 2011, that included leading hematologists, oncologists, radiation oncologists, patho

50 Currently, nephrologists, hematologist-oncologists, neurologists, and transplant s

51 16 725 for general internists to $40 495 for hematologists-oncologists.

52 atic sample of 5% of medical oncologists and hematologist/oncologists listed in the membership direct

53 tional call for surge capacity that involves hematologists/oncologists across the country in the disa

54 ts that would require extensive support from hematologists/oncologists across the country.

55 survivors return to the care of their local hematologists/oncologists or primary care physicians, wh

56 ogists, gynecologic oncologists, urologists, hematologists, pediatric oncologists, and surgeons) shou

57 of immune thrombocytopenic purpura, when the hematologist plays a consultative role, priority should

58 itutionally supported systems-based clinical hematologist positions that predominantly focus on nonma

59 to ensure sustainable professional roles for hematologists, reliable patient access to optimal hemato

60 Two hundred sixteen (5.0%) oncologists and hematologists responded to our survey.

61 en the blood bank, pharmacy, administration, hematologists, surgeon, and anesthesiologist to ensure t

62 Despite the perception by hematologists that this disease has already been conquer

63 the diagnosis is intentional and credited to hematologists, the discovery of MGUS is most often incid

64 questions was sent to 4,239 oncologists and hematologists throughout the United States.

65 mostasis, it is incumbent on the part of the hematologist to be able to carry out a logical clinical

66 aly management, will continue to require the hematologist to select therapeutic options carefully in

67 and radiographic clues that should alert the hematologist to the possibility of mucormycosis, and agg

68 of issues and communication between clinical hematologists, transplantation physicians, and transfusi

69 concerns were that referring oncologists and hematologists wanted to treat by themselves with nonradi

70 ent and treatment options for the practicing hematologist, we propose elements of a new research agen

71 arios was mailed to American oncologists and hematologists who practice medical oncology.

72 provides interested scientists and clinical hematologists with a genome-based approach toward the st

73 zebrafish as a model organism have provided hematologists with an additional genetic system to study